Category: Clinical Update
Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia
H&O What study data led the US Food and Drug Administration (FDA) to approve venetoclax for chronic lymphocytic leukemia (CLL)? SO In CLL, venetoclax (Venclexta, AbbVie/Genentech) […]
New Treatment Options for the Management of Acute Graft-Versus-Host Disease
H&O What is the pathophysiology of graft-vs-host disease? YC Allogeneic hematopoietic transplant is a therapy used mainly for hematologic malignancies. The putative therapeutic mechanism behind […]
Treatment Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm
H&O What is blastic plasmacytoid dendritic cell neoplasm (BPDCN)? NP BPDCN is an aggressive cancer of the blood and bone marrow that presents clinically as […]
Advances in the Management of Patients With Carcinoid Syndrome
H&O What are the symptoms of carcinoid syndrome? MK Carcinoid syndrome can occur in patients who have carcinoid tumors. Carcinoid tumors have the ability to […]
When to Initiate Treatment in Myelofibrosis
H&O What are the characteristics of myelofibrosis? CH The cardinal features of the blood cancer myelofibrosis are splenomegaly, fibrosis in the marrow, and either myeloid proliferation […]
Emerging Treatment Options for Carcinoid Syndrome
H&O What are carcinoid tumors, and which types are most likely to lead to carcinoid syndrome? MK Carcinoid tumors fall into the broader category of […]
Recent Advances in the Management of Myelofibrosis
Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Ruben A. Mesa, MD Consultant Hematologist Chair, Division of Hematology & Medical Oncology Deputy […]
When to Initiate Treatment With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 Neal D. Shore, MD, FACS Medical Director, CPI Carolina Urologic Research Center Atlantic […]
Use of Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer
Clinical Advances in Hematology & Oncology November 2015, Volume 13, Issue 11 Chris Parker, MD Consultant in Clinical Oncology Royal Marsden Hospital Sutton, United Kingdom There […]
Regorafenib in Metastatic Colorectal Cancer: Optimal Dosing and Patient Selection Recommendations
Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota In the […]
Kidney Cancer Update
Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2 Starting with this issue, Clinical Advances in Hematology & Oncology is launching a […]
Selecting Early Therapy in Prostate Cancer
Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2 Daniel Petrylak, MD, Director, Genitourinary Oncology Research Program, Codirector, Signal Transduction Program, Yale Comprehensive Cancer Center, Yale […]
Novel Treatments in Acute Lymphocytic Leukemia
Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Anthony S. Stein, MD Clinical Professor, City of Hope, Duarte, California H&O What is acute lymphocytic leukemia […]
Targeted Treatment in Sarcoma Patients
David M. Loeb, MD, PhD Associate Professor of Oncology and Pediatrics Director of the Musculoskeletal Tumor Program Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, […]
Epithelial-Mesenchymal Transition in Cancer Progression
Andrew J. Armstrong, MD Department of Medicine The Duke Prostate Center Duke Cancer Institute Duke University Medical Center Durham, North Carolina H&O What is epithelial-mesenchymal transition […]
Maintenance Therapy in the Treatment of Sarcoma
Isabelle Ray-Coquard, MD, PhD Medical Oncologist Centre Léon Bérard Lyon, France H&O What is the current treatment landscape in sarcoma? IRC When discussing sarcoma, it is important to […]
Treatment Approaches to Sarcoma in the Community Setting
Sant P. Chawla, MD, FRACP Director of Santa Monica Oncology Center Santa Monica, California H&O What is the treatment approach to sarcoma in the community setting? SC Sarcoma […]
New Therapies in Soft Tissue and Bone Sarcomas
Margaret von Mehren, MD Director, Sarcoma Program Fox Chase Cancer Center Philadelphia, Pennsylvania H&O What is the current treatment landscape in soft tissue and bone sarcomas? MvM Soft […]
Novel Treatments in Acute Myeloid Leukemia
Farhad Ravandi, MD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas H&O How common is acute […]
mTOR Inhibitors in Sarcoma
George D. Demetri, MD Director, Ludwig Center at Dana-Farber/Harvard Cancer Center and Sarcoma Center Quick Family Senior Investigator in Medical Oncology Senior Vice President for Experimental […]